Doctor profile · Federal record
Dr. Gurdeep Chhabra
Hematology & Oncology Physician (CMS: Hematology/Oncology) · California, MD
- NPI 1336173277
- Accepts Medicare
- MIPS 77.5 / 100 · 2023
- 38 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
23415 Three Notch RD Ste 2050
California, MD 206194018
(301) 373-7800
fax (301) 373-6800
Credentials & registration
- NPI registered
- July 2006 — 20 yrs on file
- Profile last updated
- December 13, 2021
- Year of graduation
- 1988 — 38 yrs since
- Specialty taxonomy
- 207RH0003X — NUCC code
- State license (1)
- Maryland #D0050686
- Medicaid
- MD #354300500
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1336173277. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
108,152
Distinct HCPCS
10
Medicare allowed
$1,573,031
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 24,480 | 22 | $1 | |
J1756 |
Injection, iron sucrose, 1 mg | 15,100 | 17 | $0 | |
J9271 |
Injection, pembrolizumab, 1 mg | 10,600 | 11 | $54 | |
J1453 |
Injection, fosaprepitant, 1 mg | 10,350 | 18 | $0 | |
J0897 |
Injection, denosumab, 1 mg | 10,321 | 17 | $23 | |
J9267 |
Injection, paclitaxel, 1 mg | 9,235 | 12 | $0 | |
J0885 |
Injection, epoetin alfa, (for non-esrd use), 1000 units | 7,600 | 30 | $7 | |
J1100 |
Injection, dexamethasone sodium phosphate, 1 mg | 3,785 | 62 | $0 | |
J2469 |
Injection, palonosetron hcl, 25 mcg | 2,330 | 52 | $1 | |
36415 |
Insertion of needle into vein for collection of blood sample | 2,307 | 532 | $8 |
In context: peer comparison
Among 2 peers in California Hematology & Oncology Physician, average services per provider: 2,943. This provider delivers 37× the peer median.Open Payments
Industry payments received
All-time total
$2,317
Transactions
59
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Pfizer INC. | 10 | $271.59 | |
| Sumitomo Pharma America, INC. | 3 | $253.06 | |
| E.R. Squibb & Sons, L.L.C. | 3 | $220.11 | |
| Janssen Biotech, INC. | 6 | $160.12 | |
| Incyte Corporation | 3 | $140.33 | |
| Novartis Pharmaceuticals Corporation | 5 | $132.17 | |
| Merck Sharp & Dohme LLC | 5 | $105.91 | |
| Puma Biotechnology, INC. | 4 | $91.04 | |
| Celgene Corporation | 4 | $85.21 | |
| Alexion Pharmaceuticals, INC. | 3 | $69.62 | |
| Lilly USA, LLC | 3 | $66.96 | |
| Emd Serono, INC. | 3 | $66.09 | |
| Rigel Pharmaceuticals, INC. | 3 | $65.61 | |
| Abbvie INC. | 2 | $61.84 | |
| Genzyme Corporation | 2 | $61.07 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
676
Patients
173
Total drug cost
$890,967
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Letrozole | Generic | 176 | 41 | $4,696 |
| Eliquis (Apixaban) | Brand | 104 | 27 | $68,945 |
| Pantoprazole Sodium | Generic | 59 | 18 | $939 |
| Warfarin Sodium | Generic | 58 | 0 | $711 |
| Dexamethasone | Generic | 35 | 19 | $914 |
| Ondansetron Hcl | Generic | 32 | 19 | $484 |
| Xtandi (Enzalutamide) | Brand | 30 | 0 | $419,693 |
| Raloxifene Hcl | Generic | 29 | 0 | $2,333 |
| Alendronate Sodium | Generic | 28 | 12 | $421 |
| Potassium Chloride | Generic | 25 | 14 | $179 |
Hospital affiliations
Frequently asked questions
What is Dr. Gurdeep Chhabra's medical specialty?
Dr. Gurdeep Chhabra practices Hematology & Oncology Physician in California, MD.
Where does Dr. Gurdeep Chhabra practice?
Dr. Gurdeep Chhabra practices at 23415 Three Notch RD Ste 2050, California, MD 206194018. Office phone: 3013737800.
What is Dr. Gurdeep Chhabra's NPI?
Dr. Gurdeep Chhabra's National Provider Identifier (NPI) is 1336173277, issued by NPPES.
Does Dr. Gurdeep Chhabra accept Medicare assignment?
Yes. Dr. Gurdeep Chhabra accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Gurdeep Chhabra commonly perform?
Top Medicare-reported procedures in 2023: Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS Q0138); Injection, iron sucrose, 1 mg (HCPCS J1756); Injection, pembrolizumab, 1 mg (HCPCS J9271). Source: CMS Medicare Physician & Other Practitioners file.